Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MT103: Phase I data

In a dose-escalation Phase I trial in 15 evaluable patients who received

Read the full 124 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE